AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Imiquimod Plus HSV Vaccine Cuts Recurrence Rate 80%.(Brief Article)
2001 APR 18 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The immune modulator imiquimod can dramatically decrease genital outbreaks of herpes simplex virus (HSV), especially when used with HSV vaccine.
C.J. Harrison and colleagues at Creighton University, Nebraska, evaluated imiquimod alone or in combination with HSV vaccine in animals inoculated genitally with HSV. Their findings were published in Vaccine.
Animals infected with HSV-2 were allowed to recover, then randomized to receive placebo, imiquimod alone for days 16 through 37, or the imiquimod regimen in addition to HSV-2 glycoprotein vaccine on days 16 and 37.
Imiquimod alone reduced recurrences 62.6% compared to placebo, while imiquimod plus vaccine reduced recurrences 80.6%, Harrison and team reported. This effect lasted through 14 weeks of follow-up in the imiquimod-plus-vaccine group, while it only lasted through 10 weeks in the imiquimod-alone group ("Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine," Vaccine, 2001;19(13-14):1820-1826).
Harrison et al. linked the reduction in recurrence to an increased in vitro, HSV-induced, interleukin 2 response and natural killer cell activity ...
- Cantab Pharmaceuticals' DISC HSV Herpes Vaccine Shows Safety and Immunogenicity...
- Press release article from: PR Newswire May 18, 1998 700+ words
...low to mid-dose levels of DISC HSV, not only help to validate the mechanism of action of the DISC HSV vaccine, but also provide valuable support...addition to our work with the DISC HSV vaccine, we are developing a new gene delivery...
- Cantab Reports Positive Phase I Clinical Trial Results for DISC HSV Genital...
- Press release article from: PR Newswire September 23, 1999 700+ words
...Phase I clinical trial with its DISC HSV vaccine for genital herpes being developed...the safety and immunogenicity of DISC HSV at three dose levels. In this part...previously infected (seronegative). DISC HSV immunogenicity was evaluated by measuring...
- Glaxo Wellcome and Cantab Commence Phase II Trials with DISC HSV Genital Herpes...
- Press release article from: PR Newswire November 4, 1999 700+ words
...in the Phase II trial with its DISC HSV vaccine for genital herpes. The vaccine is...the Phase I trial demonstrate DISC HSV's potential both to treat and prevent...recurrent genital herpes. The DISC HSV Product DISC (Disabled Infectious...
- HSV-1 likely cause of new genital infections.(Infectious Diseases)(Herpes...
- Magazine article from: Internal Medicine News Mechcatie, Elizabeth November 15, 2005 700+ words
...vulvovaginal diseases. Young, sexually active women are more susceptible to HSV-1 because most do not have protective antibodies to HSV-1 due to the dramatic drop in childhood HSV-1 infections, said Dr. Hillier, director, reproductive infectious...
- HSV-2 underrecognized in HIV-positive patients: subclinical...
- Magazine article from: OB GYN News September 15, 2003 700+ words
...But it is now known that even asymptomatic HSV-2 infection can increase HIV transmissibility. "Both subclinical and clinical HSV-2 reactivation increase the frequency...a Seattle HIV clinic, 172 (70%) were HSV-2 seropositive; 42 had a history of symptomatic...
- HSV-2 Acquisition In Pregnancy High If Partner Infected: Partner testing is...
- Magazine article from: OB GYN News DeMott, Kathryn October 15, 2001 700+ words
...risk for contracting primary herpes simplex virus type 2 (HSV-2) infection, said Dr. Gardella of the University...to herpes but their partner was seropositive for either HSV-1, HSV-2, or both. Of the 125 women who were susceptible to...
- Vaccine prevents genital HSV infection in seronegative women but not in...
- Newspaper article from: Vaccine Weekly January 22, 2003 700+ words
...A vaccine containing the herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit and adjuvants was effective in preventing HSV infection in women who were seronegative for both HSV-1 and HSV-2 at baseline, according to a report in...
- Vaccine prevents genital HSV infection in seronegative women but not in...
- Magazine article from: Women's Health Weekly January 23, 2003 700+ words
...A vaccine containing the herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit and adjuvants was effective in preventing HSV infection in women who were seronegative for both HSV-1 and HSV-2 at baseline, according to a report in...
Source: HighBeam Research, Imiquimod Plus HSV Vaccine Cuts Recurrence Rate 80%.(Brief Article)